[{"orgOrder":0,"company":"Pharmaceutics International","sponsor":"Humanetics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Genistein","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Pharmaceutics International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pharmaceutics International \/ Humanetics Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Pharmaceutics International \/ Humanetics Corporation"}]

Find Clinical Drug Pipeline Developments & Deals by Pharmaceutics International

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Partnership will support clinical trial studies of BIO 300 in COVID-19 patients.

                          Brand Name : BIO 300

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 19, 2020

                          Lead Product(s) : Genistein

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Humanetics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank